Key Summary: On October 20, 2024, Starboard issued an investor presentation analyzing Pfizer Inc., highlighting its contributions to public health during the COVID-19 pandemic through its vaccine and treatments. It noted that Pfizer's stock had underperformed compared to peers, leading to a market value decline of $20 to $60 billion since 2019.
Market Cap: $163 billion | Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally.
On October 20, 2024, Starboard issued an investor presentation outlining its analysis of Pfizer Inc., emphasizing its significant contributions to public health during the COVID-19 pandemic through its vaccine and antiviral treatments. However, it notes that Pfizer's stock has dramatically underperformed relative to peers, resulting in a market value decline of $20 to $60 billion since 2019. Starboard identifies issues related to innovation, capital allocation, and R&D efficiency, suggesting that a renewed focus on execution and innovation could enhance Pfizer's valuation and performance.
Comments